Unauthorized Outside Channels In Abundance †Myassignmenthelp.Com

Question: Discuss About The Unauthorized Outside Channels In Abundance? Answer: Introducation Unwanted pregnancies are one of the rising public health concerns in the current age and with the advancements in the health care industry progressing a little every day, there are a lot of choices in the market for the mothers who do want to pursue with the pregnancy, and medical abortion is one such choice for the unwilling mothers. Medical abortion can be described as the phenomenon of using medical drugs or pills to terminate a pregnancy in the early stage (Trussell et al., 2014). It is also known as non surgical abortion or medication abortion as abortifacient drugs are used to terminate a pregnancy, early and easy. The concept of early medical abortion was introduced in the 1970s when the prostaglandin analogue drugs were introduced, and the very first abortifacient drug introduced in the market had been mifepristone, followed by misoprostol in the 1980s (Sanhueza Smith et al., 2014). According to a report by the World health organization, the safe abortion policy describes the main purpose behind the medical abortion being used in the health care is to provide the women the access to a safe and home- based option who do not have access to surgical interventions. However, the exploitation of the medical abortion pills has raised a concern for the entire health care industry (Baird 2015). Taking the Australian context under consideration, the abortion pills like mifepristone is a widely used medical abortion pill, utilized abundantly in both the clinical settings and in home based care scenario. The more abortion techniques like the surgical dilation and curettage are considered to be potentially risky for the health and safety of the women who undergo it, medical abortion pills on the other hand had been a lesser evil, as it providers a much safer abortion experience to the women. However, taking the Australian context into consideration, the restrictive obstructions by the Federal Goods Administration legislation have been restricting the availability of the medical abortion until 2006 (Baird 2015). And the medical abortion drugs have been allowed commercial import only in 2012 in Australia, and mifepristone had become a government subsidized medication only in the year of 2013. Elaborating more on the development of the concept of medical abortion in Australia, the initiation of the use of mifepristone occurred in the late 1990s around in The New South Wales and Victoria, and the medication was tested as both emergency contraceptive and abortifacient in the early phase. H owever, the availability of the medical abortion was obstructed in the 1996, by the conservative government of PM John Howard, creating a new legislation mandating special condition or the use of mifepristone, effectively banning the use of the drug commercially (Costa et al., 2015). The movements of the Abortions Providers Federation of Australia had been a slow but steady work in progress in facilitating the entry of the medication as any other normal drug in Australia. The cumulative work of both the federation and female federal parliamentarians was successful in the lifting the ban on mifepristone around 2006, however the import allowance for the medication took a few years to be materialized; although time gap served to facilitate the time consuming process of physicians becoming authorized prescribers of the drug (Doran and Nancarrow 2015). Within the 2012, 200 doctors practising in Australia become authorized prescribers of abortifacient pills, and the process of ensuring av ailability of abortifacient drugs in Australia was escalated a few more steps. In August, 2012, a subsidiary company in the name of Marie stopes was established which could extract the authorized registration for the two abortifacient pills from the Therapeutic Goods Administration, for mifepristone Linepharma and misoprostol GyMiso. Since the entry of the medical abortion pills in the year 2012, it has been abundantly used in the market and the alarming use of this drug in the present day scenario is one of the emerging public health priorities (Grossman and Goldstone 2015). Even during the prolonged wait period for the authorized access for the drug, the perception of the Australian women about the abortifacient drugs have been growing, and the restrictions for the drug in Australia only fed the raging demand for the pills in the women. As soon as medication was available in the Australian market in the 2013, the outrage for early medical abortion began in Australia (Newton et al., 2016). Even before the drug was legitimately available in the Australian markets, women in Australia were reported to obtain it from outside channels. Many of the underage women had also been reported being arrested in the Australian market due to unauthorized usage of abortion pills in Australia. After it was made available in Australian market legitimately, mifepristone was the most exploited drug accessed through unauthorized outside channels in abundance (ORourke, Belton and Mulligan 2016). With the demand for early medical abortion extremely high in the Australian women, the drug soon became enlisted under the pharmaceutical benefits scheme. However, with the extreme demand and availability, there have been a number of serious adverse effects of this development of early medical abortion in Australia. First and foremost, there have been serious concerns regarding the cost effectiveness of the medication abortion, while some regions reported it to be cheaper than the surgical alternative, where as in some regions it was reported to cost more than the surgical alternative altogether (Baird 2015). Along with that post abortive care for the poorer women with limited access to better health care and lifestyle standards suffered the consequences of unwarranted use of abortion pills by the means of over the counter unauthorized purchase. The complete absence of coordinated action by public health departments in Australia can one of the most vital contributing factors behind the chaos in context of medical abortion pills and its availability (Oppegaard et al., 2017). On a concluding note, the legitimate introduction of medical abortion pills in the Australian market has undoubtedly been a blessing for the women to successfully and safely undergo abortion without having to resort to surgical interventions. However, the need for regulatory precaution and post operative management is crucial, which in case of unauthorized outside channel access of the medication will not provide. The extreme cost for authorized usage of these pills can be the reason propelling the Australian women belonging to low economic standards to resort to over the counter usage. Hence, there is need for interference from the public health authorities so that the pain staking process of medical development or medication abortion does not eventually lead to adverse consequences for the women. References: Baird, B., 2015. Medical abortion in Australia: a short history. Reproductive health matters, 23(46), pp.169-176. Costa, C., Douglas, H., Hamblin, J., Ramsay, P. and Shircore, M., 2015. Abortion law across Australiaa review of nine jurisdictions. Australian and New Zealand Journal of Obstetrics and Gynaecology, 55(2), pp.105-111. Doran, F. and Nancarrow, S., 2015. Barriers and facilitators of access to first-trimester abortion services for women in the developed world: a systematic review. J Fam Plann Reprod Health Care, 41(3), pp.170-180. Grossman, D. and Goldstone, P., 2015. Mifepristone by prescription: a dream in the United States but reality in Australia. Contraception, 92(3), pp.186-189. Newton, D., Bayly, C., McNamee, K., Hardiman, A., Bismark, M., Webster, A. and Keogh, L., 2016. How do women seeking abortion choose between surgical and medical abortion? Perspectives from abortion service providers. Australian and New Zealand Journal of Obstetrics and Gynaecology, 56(5), pp.523-529. ORourke, A., Belton, S. and Mulligan, E., 2016. Medical abortion in Australia: What are the legal and clinical risks? Is medical abortion over-regulated?. Journal of Law and Medicine, 221. Oppegaard, K.S., Sparrow, M., Hyland, P., Garca, F., Villarreal, C., Fandes, A., Miranda, L. and Berer, M., 2017. What if medical abortion becomes the main or only method of first trimester abortion? A roundtable of views. Contraception. Sanhueza Smith, P., Pea, M., Dzuba, I.G., Martinez, M.L.G., Peraza, A.G.A., Bousiguez, M., Shochet, T. and Winikoff, B., 2014. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. Reproductive health matters, 22(sup44), pp.75-82. Trussell, J., Nucatola, D., Fjerstad, M. and Lichtenberg, E.S., 2014. Reduction in infection-related mortality since modifications in the regimen of medical abortion. Contraception, 89(3), pp.193-196.